Naiyer A. Rizvi
0000-0002-1134-7494
Publication & Citation Trends
Publications
0 total
Abstract 6740: Selective immune activation of antigen activated T cells with STK-012, an a/b IL-2 receptor biased partial agonist, with pembrolizumab and chemotherapy in 1L PD-L1 negative non-squamous NSCLC
Cited by 0
Semantic Scholar
516 An open-label, phase II multicenter study of rituximab or tocilizumab for steroid-dependent or steroid-refractory immune-related adverse events due to immune checkpoint inhibitors
Cited by 0
Semantic Scholar
1345 Initial phase 1a/1b results of STK-012, an α/β IL-2 receptor biased partial agonist, with pembrolizumab, pemetrexed, and carboplatin in 1L PD-L1 negative non-squamous NSCLC
Cited by 0
Semantic Scholar
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors OA
Cited by 2
Semantic Scholar
Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
Cited by 0
Semantic Scholar
Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner/disciplinary working group perspective
Cited by 1
Semantic Scholar
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors
Cited by 0
Semantic Scholar
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)
Cited by 4
Semantic Scholar
1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors OA
Cited by 0
Semantic Scholar
Classification of current anticancer immunotherapies
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(235)
Lung Cancer Treatments and Mutations
(219)
Cancer Genomics and Diagnostics
(90)
Lung Cancer Research Studies
(84)
Colorectal Cancer Treatments and Studies
(56)
Affiliations
AstraZeneca (United Kingdom)
Southern Research Institute
Western University
Boston Medical Center
Amgen (United States)